Volume 5, Issue 10

Emerging MS Clinical Options

In this issue:

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?

Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review

Learning objectives:

  • Discuss the current status of BTK inhibitors under investigation for treatment of MS.
  • Describe the potential benefits of extended interval or alternative B cell depletion dosing for RRMS patients stable on B cell depletion therapy.
  • Discuss the randomized controlled trials comparing HSCT to high efficacy DMTs in patients with RRMS and active SPMS.

Author:

Cole Harrington, MD, PhD
Cole Harrington, MD, PhD

Assistant Professor in Neurology
Department of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: October 24, 2023
Expiration date: October 23, 2025